Yahoo Finance

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, TTI-621, is a SIRPaFc fusion protein ...
Yahoo Finance

Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47

TORONTO, ONTARIO--(Marketwired - Feb 3, 2016) - Trillium Therapeutics Inc. (TRIL)(TR.TO) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today ...
Yahoo UK & Ireland

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress

TORONTO, ONTARIO--(Marketwired - Jun 7, 2016) - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will ...
ascopubs.org

A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible ...

A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult ...
Business Insider

Trillium Therapeutics to Report Preclinical Data on TTI-621 and TTI-622 at the AACR Annual Meeting 2018

TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
Yahoo Finance

Trillium Therapeutics to Present at Upcoming Scientific Conferences

TORONTO, ONTARIO--(Marketwired - Nov. 6, 2017) - Trillium Therapeutics Inc. (TRIL.TO)(TRIL.TO) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
Nasdaq

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma

CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, ...
ascopubs.org

TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).

A phase I study of duvelisib in combination with oral azacitidine (CC-486) in relapsed lymphoid malignancies. Background: CD47 is an innate immune checkpoint that binds signal regulatory protein alpha ...
Yahoo Finance

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

TORONTO, ONTARIO--(Marketwired - May 31, 2017) - Trillium Therapeutics Inc. (TRIL)(TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will ...